• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于临床常规应用的多发性骨髓瘤低输入材料的RNA测序

RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine.

作者信息

Seckinger Anja, Bähr-Ivacevic Tomi, Benes Vladimir, Hose Dirk

机构信息

Labor für Myelomforschung, Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Genomics Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany.

出版信息

Methods Mol Biol. 2018;1792:97-115. doi: 10.1007/978-1-4939-7865-6_7.

DOI:10.1007/978-1-4939-7865-6_7
PMID:29797254
Abstract

RNA sequencing is a recently developed approach for transcriptome profiling with several advantages over gene expression profiling using DNA microarrays. Here we describe a RNA-sequencing protocol optimized for low-input analysis of total RNA from CD138 purified plasma cells from myeloma patients which is applicable in clinical routine.

摘要

RNA测序是一种最近开发的用于转录组分析的方法,与使用DNA微阵列进行基因表达分析相比具有多个优势。在此,我们描述了一种针对骨髓瘤患者CD138纯化浆细胞的总RNA低输入量分析而优化的RNA测序方案,该方案适用于临床常规操作。

相似文献

1
RNA-Sequencing from Low-Input Material in Multiple Myeloma for Application in Clinical Routine.用于临床常规应用的多发性骨髓瘤低输入材料的RNA测序
Methods Mol Biol. 2018;1792:97-115. doi: 10.1007/978-1-4939-7865-6_7.
2
A Rapid and Robust Protocol for Reduced Representation Bisulfite Sequencing in Multiple Myeloma.一种用于多发性骨髓瘤中简化代表性亚硫酸氢盐测序的快速且稳健的方案。
Methods Mol Biol. 2018;1792:179-191. doi: 10.1007/978-1-4939-7865-6_13.
3
Development of an RNA sequencing-based prognostic gene signature in multiple myeloma.基于 RNA 测序的多发性骨髓瘤预后基因特征的建立。
Br J Haematol. 2021 Jan;192(2):310-321. doi: 10.1111/bjh.16744. Epub 2020 May 15.
4
The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?全基因组测序(WGS)与RNA测序(RNA-Seq)相结合在多发性骨髓瘤诊断中优于传统诊断测试:准备好进入黄金时代了吗?
Cancer Genet. 2020 Apr;242:15-24. doi: 10.1016/j.cancergen.2020.01.001. Epub 2020 Jan 11.
5
Single-Cell RNA Sequencing of Glioblastoma Cells.胶质母细胞瘤细胞的单细胞RNA测序
Methods Mol Biol. 2018;1741:151-170. doi: 10.1007/978-1-4939-7659-1_12.
6
Protocol for MP: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma.骨髓瘤分子检测方案:一种全面且以临床为导向的靶向测序panel,用于多发性骨髓瘤的常规分子分析
Methods Mol Biol. 2018;1792:117-128. doi: 10.1007/978-1-4939-7865-6_8.
7
Gel-seq: whole-genome and transcriptome sequencing by simultaneous low-input DNA and RNA library preparation using semi-permeable hydrogel barriers.凝胶测序:使用半渗透水凝胶屏障,通过同时进行低输入量的 DNA 和 RNA 文库制备,实现全基因组和转录组测序。
Lab Chip. 2017 Jul 25;17(15):2619-2630. doi: 10.1039/c7lc00430c.
8
Preparation of Small RNA NGS Libraries from Biofluids.从生物流体中制备小RNA二代测序文库。
Methods Mol Biol. 2018;1740:163-175. doi: 10.1007/978-1-4939-7652-2_13.
9
Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.多发性骨髓瘤的分子谱分析:从基因表达分析到下一代测序。
Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S55-68. doi: 10.1517/14712598.2013.793305. Epub 2013 Apr 24.
10
Retinal transcriptome profiling by directional next-generation sequencing using 100 ng of total RNA.使用100纳克总RNA通过定向新一代测序进行视网膜转录组分析。
Methods Mol Biol. 2012;884:319-34. doi: 10.1007/978-1-61779-848-1_23.

引用本文的文献

1
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.基于 RNA 测序的多发性骨髓瘤一线治疗选择和风险评估。
Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023.
2
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma.MCT1 是多发性骨髓瘤来那度胺维持治疗的预测标志物。
Blood Adv. 2022 Jan 25;6(2):515-520. doi: 10.1182/bloodadvances.2021005532.
3
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
前瞻性靶区评估和多模态预测在 GMMG-MM5 多中心试验中多发性骨髓瘤的个体化和风险适应性治疗策略中的生存。
J Hematol Oncol. 2019 Jun 26;12(1):65. doi: 10.1186/s13045-019-0750-5.
4
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.CD38作为轻链淀粉样变性和多发性骨髓瘤的免疫治疗靶点——与分子实体、风险、生存及初始耐药机制的关联
Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.